Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Gains from Investment Securities (2020 - 2025)

Summit Therapeutics (SMMT) has disclosed Gains from Investment Securities for 7 consecutive years, with -$815000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$815000.0, compared with a TTM value of $815000.0 through Sep 2025, down 80.67%, and an annual FY2024 reading of $4.2 million, up 8007.69% over the prior year.
  • Gains from Investment Securities was -$815000.0 for Q4 2025 at Summit Therapeutics, up from -$2.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.7 million in Q3 2024 and bottomed at -$4.2 million in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $546928.6, with a median of $544500.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities plummeted 36066.67% in 2021, then soared 56225.0% in 2025.
  • Year by year, Gains from Investment Securities stood at $3.4 million in 2021, then crashed by 181.47% to -$2.8 million in 2022, then plummeted by 52.14% to -$4.2 million in 2023, then skyrocketed by 258.79% to $6.7 million in 2024, then tumbled by 112.24% to -$815000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for SMMT at -$815000.0 in Q4 2025, -$2.9 million in Q3 2025, and $2.3 million in Q2 2025.